CompletedNCT00600756
Quetiapine XR or risperidone and well-being in schizophrenia
About this title
Read the official source — NCT00600756Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Assebroek and 115 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 798
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Switzerland, Belgium, Brazil, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00600756
- Official title
Show the full official title
A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated With Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in a Naturalistic Setting
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Assebroek, Belgium · Hasselt, Belgium · Liège, Belgium
112 more locations
- Montignies-sur-Sambre, Belgium
- Roeselare, Belgium
- Sint-Denijs-Westrem, Belgium
- Tournai, Belgium
- Fortaleza, Brazil
- Salvador, Brazil
- Aparecida de Goiânia, Brazil
- Belo Horizonte, Brazil
- Curitiba, Brazil
- Recife, Brazil
- Rio de Janeiro, Brazil
- Porto Alegre, Brazil
- Itapira, Brazil
- Ribeirão Preto, Brazil
- São Paulo, Brazil
- Sorocaba, Brazil
- Botucatu, Brazil
- Cerova Koria Village, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Stara Zagora, Bulgaria
- Varna, Bulgaria
- Barrio Los Yoses, Costa Rica
- Curridabat, Costa Rica
- Guadalupe, Costa Rica
- Helsinki, Finland
- Kitee, Finland
- Kuopio, Finland
- Lapua, Finland
- Pori, Finland
- Raahe, Finland
- Rovaniemi, Finland
- Tampere, Finland
- Turku, Finland
- Bad Saarow, Germany
- Berlin, Germany
- Bielefeld, Germany
- Bochum, Germany
- Butzbach, Germany
- Cologne, Germany
- Darmstadt, Germany
- Duisburg, Germany
- Gelsenkirchen, Germany
- Grevenbroich, Germany
- Hamburg, Germany
- Hattingen, Germany
- Hildesheim, Germany
- Königsbrück, Germany
- Mittweida, Germany
- München, Germany
- Oranienburg, Germany
- Siegen, Germany
- Stralsund, Germany
- Wismar, Germany
- Andria, Italy
- Feltre, Italy
- Maddaloni, Italy
- Sora, Italy
- Genova, Italy
- Milan, Italy
- Perugia, Italy
- Fidenza, Italy
- Parma, Italy
- Palmi, Italy
- Rimini, Italy
- Salerno, Italy
- Sassari, Italy
- Chioggia, Italy
- Ancona, Italy
- Pompei, Italy
- México, Mexico
- Monterrey, Nuevo Leon, Mexico
- San Luis Potosí City, Mexico
- Guadalajara Jalisco, Mexico
- Yucatán, Mexico
- Abraveses, Portugal
- Braga, Portugal
- Coimbra, Portugal
- Lisbon, Portugal
- Porto, Portugal
- Santarém, Portugal
- Piteşti, Romania
- Galati, Romania
- Bucharest, Romania
- Craiova, Romania
- Sibiu, Romania
- Moscow, Russia
- Kazan', Russia
- Saint Petersburg, Russia
- Jaén, Spain
- Málaga, Spain
- Seville, Spain
- Zamudio (vizcaya), Spain
- Salamanca, Spain
- Zamora, Spain
- Mataro (barcelona), Spain
- Vigo, Spain
- Madrid, Spain
- Langreo, Spain
- Elche (alicante), Spain
- Sant Joan d'Alacant, Spain
- Prilly, Switzerland
- Wil, Switzerland
- Istanbul, Türkiye
- Manisa, Türkiye
- Ankara, Türkiye
- Elâzığ, Türkiye
- Izmir, Türkiye
- Russia
- Türkiye
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine XR and Risperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...